Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Issue 4 (11th May 2019)

• Record Type: Journal Article
• Authors: Rennert, Robert C; Khan, Usman; Bartek, Jiri; Tatter, Stephen B; Field, Melvin; Toyota, Brian; Fecci, Peter E; Judy, Kevin; Mohammadi, Alireza M; Landazuri, Patrick; Sloan, Andrew E; Kim, Albert H; Leuthardt, Eric C; Chen, Clark C
• Is Part Of: Neurosurgery. Volume 86:Issue 4(2020)
• Page Start: 538
• Page End: 547
• Publication Date: 2019-05-11
• Subjects: Stereotactic laser ablation -- Neuro-oncology -- Safety; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1093/neuros/nyz141
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: BACKGROUND: Stereotactic laser ablation (SLA) has demonstrated potential utility for a spectrum of difficult to treat neurosurgical pathologies in multiple small and/or retrospective single-institutional series. Here, we present the safety profile of SLA of intracranial lesions from the Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN; Monteris Medical) multi-institutional, international prospective observational registry. OBJECTIVE: To determine the procedural safety of SLA for intracranial lesions. METHODS: Prospective procedural safety and hospitalization data from the first 100 treated LAANTERN patients was collected and analyzed. RESULTS: Mean age and baseline Karnofsky Performance Status (KPS) were 51(± 17) yr and 83(± 15), respectively. In total, 81.2% of patients had undergone prior surgical or radiation treatment. Most patients had a single lesion (79%) ablated through 1 burr hole (1.2 ± 0.7 per patient), immediately following a lesion biopsy. In total, >90% of the lesion was ablated in 72% of treated lesions. Average total procedural time was 188.2 ± 69.6 min, and average blood loss was 17.7 ± 55.6 ccs. The average length of intensive care unit (ICU) and hospital stays before discharge were 38.1 ± 62.7 h and 61.1 ± 87.2 h, respectively. There were 5 adverse events (AEs) attributable to SLA (5/100; 5%). After the procedure, 84.8% of patients were discharged home. There was 1 mortality within 30 d of the procedure (1/100; 1%), which was not attributable to SLA. CONCLUSION: SLA is a safe, minimally invasive procedure with favorable postprocedural ICU and hospital utilization profiles.